Sotera Health (NASDAQ:SHC) Receives “Overweight” Rating from Piper Sandler

Piper Sandler restated their overweight rating on shares of Sotera Health (NASDAQ:SHC) in a report published on Friday,Benzinga reports. The firm currently has a $25.00 price objective on the stock, up from their previous price objective of $22.00.

Other research analysts also recently issued reports about the company. Wall Street Zen downgraded Sotera Health from a “strong-buy” rating to a “buy” rating in a research note on Saturday, April 11th. Citigroup upped their target price on shares of Sotera Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research report on Friday. The Goldman Sachs Group initiated coverage on shares of Sotera Health in a research note on Friday, June 5th. They set a “buy” rating and a $20.00 target price for the company. Weiss Ratings upgraded Sotera Health from a “hold (c-)” rating to a “hold (c)” rating in a research report on Thursday, July 9th. Finally, JPMorgan Chase & Co. lifted their target price on Sotera Health from $16.00 to $18.00 and gave the stock a “neutral” rating in a report on Friday. Eight analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to MarketBeat.com, Sotera Health presently has an average rating of “Moderate Buy” and a consensus price target of $21.50.

Sotera Health Price Performance

NASDAQ:SHC opened at $18.86 on Friday. The company has a quick ratio of 2.54, a current ratio of 2.80 and a debt-to-equity ratio of 3.19. The business’s 50-day simple moving average is $17.13 and its two-hundred day simple moving average is $16.33. The stock has a market cap of $5.38 billion, a PE ratio of 33.09 and a beta of 1.77. Sotera Health has a 52 week low of $12.94 and a 52 week high of $19.85.

Sotera Health (NASDAQ:SHC) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.02. Sotera Health had a return on equity of 40.12% and a net margin of 13.44%.The firm had revenue of $321.38 million during the quarter, compared to analyst estimates of $309.70 million. During the same quarter in the prior year, the company posted $0.20 earnings per share. The business’s quarterly revenue was up 9.2% compared to the same quarter last year. Sotera Health has set its FY 2026 guidance at 0.950-1.010 EPS. As a group, analysts forecast that Sotera Health will post 0.87 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gtcr Investment Xi Llc sold 12,735,301 shares of the business’s stock in a transaction on Wednesday, May 13th. The shares were sold at an average price of $15.17, for a total value of $193,194,516.17. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 15.36% of the company’s stock.

Hedge Funds Weigh In On Sotera Health

A number of institutional investors and hedge funds have recently made changes to their positions in SHC. IFP Advisors Inc increased its holdings in shares of Sotera Health by 1,105.6% in the 4th quarter. IFP Advisors Inc now owns 1,495 shares of the company’s stock worth $26,000 after buying an additional 1,371 shares during the last quarter. Rothschild Investment LLC purchased a new stake in shares of Sotera Health during the 4th quarter valued at about $27,000. Root Financial Partners LLC lifted its holdings in shares of Sotera Health by 217.5% in the 1st quarter. Root Financial Partners LLC now owns 2,124 shares of the company’s stock valued at $30,000 after acquiring an additional 1,455 shares during the last quarter. Meeder Asset Management Inc. bought a new position in shares of Sotera Health in the 2nd quarter valued at about $37,000. Finally, EverSource Wealth Advisors LLC grew its position in Sotera Health by 831.4% in the second quarter. EverSource Wealth Advisors LLC now owns 3,288 shares of the company’s stock worth $37,000 after acquiring an additional 2,935 shares in the last quarter. 91.03% of the stock is owned by hedge funds and other institutional investors.

Key Stories Impacting Sotera Health

Here are the key news stories impacting Sotera Health this week:

• Positive Sentiment: Strong Q2 results and raised outlook: Sotera Health reported adjusted EPS of $0.26, above the $0.24 consensus, while revenue increased 9.2% year over year to $321.4 million, exceeding estimates of $309.7 million. Adjusted EBITDA rose 10%, and net income increased to $53.6 million from $8.0 million a year earlier. Sotera Health Delivers Strong Second-Quarter and First-Half 2026 Results and Raises FY 2026 Outlook
• Positive Sentiment: Management raised full-year 2026 guidance: The company increased its constant-currency revenue growth outlook to 5.25%-6.75%, adjusted EBITDA growth outlook to 5.75%-7.25%, and adjusted EPS guidance to $0.95-$1.01. It also expects lower interest expense following a term-loan repricing that should save approximately $3.5 million annually. Sotera Health Company Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Piper Sandler became more bullish: The firm reaffirmed its “overweight” rating and raised its price target from $22 to $25, implying substantial upside from the recent trading level. Benzinga analyst update
• Neutral Sentiment: JPMorgan’s target increase was less constructive: JPMorgan lifted its target from $16 to $18 but maintained a “neutral” rating, leaving its target below the current share price. This may be limiting enthusiasm following the earnings-driven rally. Benzinga analyst update
• Negative Sentiment: Leverage and ongoing risks remain: SHC still carries approximately $2.2 billion of debt, while litigation related to ethylene oxide facilities, inflationary costs and regulatory risks remain potential overhangs. The stock’s valuation also appears demanding relative to JPMorgan’s neutral view.

Sotera Health Company Profile

Sotera Health Inc (NASDAQ: SHC) is a global provider of sterilization and laboratory testing services that support the medical device, pharmaceutical, life sciences and consumer product industries. Headquartered in Jacksonville, Florida, the company offers a suite of services designed to ensure products meet rigorous safety and regulatory requirements before reaching market.

Sotera Health operates through three primary service platforms. Its Sterigenics division delivers contract sterilization solutions, including ethylene oxide (EtO), gamma irradiation, electron beam and X-ray technologies.